Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.681
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore

International Journal of Technology Assessment in Health Care
Health Policy
2019English

Pcn94 - Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients With Advanced Renal Cell Carcinoma in the Uk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn165 - Cost-Effectiveness of Sorafenib for Metastatic Renal Cell Carcinoma: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer

Current Oncology
Oncology
2013English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy